DDS Debuts FX-8, Transforming Automated Infused-Flower Production

The FX-8 transforms cannabis infusion by integrating advanced automation, ultra-fine atomization, and robust industrial reliability. It ensures the production of consistently coated, premium flower with unmatched efficiency, enhanced safety, and greater scalability. DETROIT, Nov. 25, 2025 — Detroit Dispensing Solutions (DDS) is once again innovating in cannabis manufacturing with the…

Korea Innovation Foundation Selects Bio Health Innovators LEEBIO and Airlab for North American Global Technology Commercialization Program

DAEJEON, South Korea, Nov. 26, 2025 — The Korea Innovation Foundation (INNOPOLIS), currently overseeing the 2025 Global Technology Commercialization Support Program (North America), has announced the selection of two innovative companies, LEEBIO and Airlab, for this initiative. This program is designed to support pioneering technology companies in fields such as…

Middle East officials anticipate second phase of Israel-Hamas ceasefire while two hostages remain in Gaza.

Officials gathered in Cairo on Wednesday to deliberate on the second stage of the Israel-Hamas ceasefire agreement.Reports indicate that the intelligence chiefs from Turkey and Egypt, along with Qatar's prime minister, reportedly attended the meeting.Attendees reportedly consented to further enhance coordination and collaboration with the Civil Military Coordination Center. This…

CBL International Limited Wins Prestigious ‘CGMA Excellent Sustainability Award’ at the CGMA Annual Awards 2025

KUALA LUMPUR, Nov 26, 2025 - (ACN Newswire via SeaPRwire.com) – CBL International Limited (NASDAQ: BANL) (the “Company” or “CBL”), the listing vehicle of the Banle Group (“Banle” or “the Group”), is proud to announce that it has been awarded the “CGMA Excellent Sustainability Award” at the prestigious CGMA Annual Awards…

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

TOKYO and CAMBRIDGE, Mass., Nov. 26, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: HaruoNaito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has completed the rolling submission of the Supplemental Biologics License Application…